Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma Reply
2011
Abstract
The hypothesis put forward by Sorscher et al to explain survival differences in the subgroup of patients with multiple myeloma (MM) who were described in our article bears consideration, and the potential effect of zoledronic acid on survival in patients with MM and Ras mutation will require additional study.
